Showing results (91-100 of 511) with videos related to
Sort By:
Pageof 52
Organic Letters|May 25, 2002
Enantioenriched dihydropyrones from beta-lactone templatesG Greg Zipp, Mark A Hilfiker, Scott G NelsonJournal of Allied Health|May 30, 2020
Mind Mapping to Enhance Critical Thinking Skills in Physician Assistant Education: A Randomized Controlled StudyCynthia Israel, Genevieve Pinto Zipp, Michelle D'Abundo, et al.Pharmacology & Therapeutics|January 19, 2023
Interleukin-4 as a therapeutic targetYvonne Gärtner, Lynn Bitar, Frauke Zipp, et al.Nature Reviews. Neurology|May 16, 2019
Implementing the 2017 McDonald criteria for the diagnosis of multiple sclerosisFrauke Zipp, Jiwon Oh, Yara Dadalti Fragoso, et al.Journal of Oral Pathology & Medicine : Official Publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology|January 5, 2001
Frequency and predictive value of the clinical manifestations in Sjögren's syndromeI Al-Hashimi, S Khuder, N Haghighat, et al.Advances in Immunology|November 6, 2007
New insights into adaptive immunity in chronic neuroinflammationVolker Siffrin, Alexander U Brandt, Josephine Herz, et al.Journal of the Neurological Sciences|December 16, 2006
Serum levels of soluble CD95 are not associated with amelioration of multiple sclerosis during pregnancyStefan Ehrlich, Judith Haas, Frauke Zipp, et al.Cytokine & Growth Factor Reviews|August 26, 2014
IL-17 and related cytokines involved in the pathology and immunotherapy of multiple sclerosis: Current and future developmentsDirk W Luchtman, Erik Ellwardt, Catherine Larochelle, et al.Cytokine|November 12, 2003
Regulation of soluble and surface-bound TRAIL in human T cells, B cells, and monocytesStefan Ehrlich, Carmen Infante-Duarte, Bibiane Seeger, et al.Journal of Neuro-Oncology|March 5, 1999
Soluble CD95 (Fas/APO-1) in malignant glioma: (no) implications for CD95-based immunotherapy?J R Streffer, M Schuster, F Zipp, et al.Pageof 52